Elanco Animal Health Inc(ELAN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,703 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ELAN
Events flagged as statistical outliers against ELAN's own multi-year baseline — not fixed dollar thresholds.
- Record insider buy2026-08-20
Largest insider buy on record for ELAN: Kurzius Lawrence Erik purchased $935,920
View source filing → - Insider cluster2026-08-20
5 insiders bought $1,473,069 of ELAN in 30 days — 5.3σ above this company's 2-year norm
View source filing → - Insider cluster2026-08-18
4 insiders bought $537,149 of ELAN in 30 days — 4.2σ above this company's 2-year norm
View source filing → - Insider cluster2026-08-12
3 insiders bought $442,876 of ELAN in 30 days — 3.1σ above this company's 2-year norm
View source filing →
ELAN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Elanco Animal Health Inc (ELAN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ELAN at 48.7/100 on a 32-signal composite quality model, placing it at rank #1,703 of 2,961 stocks — the bottom half of the AI-ranked universe. ELAN scores in the top quartile across earnings quality (90.8), revenue scale (77.8). Areas of concern include profitability (22.4) and balance sheet strength (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 47.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Elanco Animal Health Inc reports quarterly revenue of $1.4B, net income of $54.0M, free cash flow of $244.0M. Top institutional holders of ELAN by reported 13-F value include DODGE & COX, FMR, BlackRock, based on the most recent SEC filings. ELAN trades on the NYSE exchange and files with the SEC under CIK 1739104. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELAN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elanco Animal Health Inc directly from SEC EDGAR. Elanco Animal Health Inc's 13F Pro composite quality score has ranged between 35 and 62 since 2021, currently 48.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.4B
Net Income
Q2 2026
$54.0M
Free Cash Flow
Q2 2026
$244.0M
ROIC
Q2 2026
2.1%
D/E Ratio
Q2 2026
0.59
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+6.2% YoYNet Income
-168.6% YoYEPS (Diluted)
-169.1% YoYTotal Assets
+5.9% YoYTotal Debt
-8.9% YoYOp. Cash Flow
+3.5% YoYFree Cash Flow
-27.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.71B +6.2% | $4.44B +0.5% | $4.42B +0.1% | $4.41B -7.4% | $4.76B +45.6% | $3.27B |
| Net Income | $-232.0M -168.6% | $338.0M +127.5% | $-1.23B -1478.2% | $-78.0M +83.9% | $-483.0M +15.9% | $-574.0M |
| EPS (Diluted) | $-0.47 -169.1% | $0.68 +127.2% | $-2.50 -1462.5% | $-0.16 +83.8% | $-0.99 +23.8% | $-1.30 |
| Total Assets | $13.36B +5.9% | $12.61B -12.2% | $14.36B -7.3% | $15.49B -6.0% | $16.48B -6.8% | $17.69B |
| Total Debt | $4.02B -8.9% | $4.41B -24.1% | $5.81B -6.6% | $6.22B -5.9% | $6.61B -1.0% | $6.68B |
| Operating Cash Flow | $560.0M +3.5% | $541.0M +99.6% | $271.0M -40.0% | $452.0M -6.4% | $483.0M +1278.0% | $-41.0M |
| Free Cash Flow | $284.0M -27.9% | $394.0M +200.8% | $131.0M -53.4% | $281.0M -13.3% | $324.0M +284.1% | $-176.0M |
Get alerted when ELAN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Elanco Animal Health Inc including:
Top Institutional Holders of ELAN
DODGE & COX
$1.7B67,397,025 shFMR LLC
$1.4B56,948,819 shBlackRock, Inc.
$1.2B48,849,973 shPRIMECAP MANAGEMENT CO/CA/
$1.1B45,445,012 shT. Rowe Price Investment Management, Inc.
$707.6M28,750,719 shDIMENSIONAL FUND ADVISORS LP
$625.5M25,417,271 shVANGUARD PORTFOLIO MANAGEMENT LLC
$558.0M22,672,312 shVANGUARD CAPITAL MANAGEMENT LLC
$556.4M22,607,532 shSTATE STREET CORP
$395.3M16,063,046 shWinslow Capital Management, LLC
$332.5M13,511,127 sh
| Fund | Value | Shares |
|---|---|---|
| DODGE & COX | $1.7B | 67,397,025 |
| FMR LLC | $1.4B | 56,948,819 |
| BlackRock, Inc. | $1.2B | 48,849,973 |
| PRIMECAP MANAGEMENT CO/CA/ | $1.1B | 45,445,012 |
| T. Rowe Price Investment Management, Inc. | $707.6M | 28,750,719 |
| DIMENSIONAL FUND ADVISORS LP | $625.5M | 25,417,271 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $558.0M | 22,672,312 |
| VANGUARD CAPITAL MANAGEMENT LLC | $556.4M | 22,607,532 |
| STATE STREET CORP | $395.3M | 16,063,046 |
| Winslow Capital Management, LLC | $332.5M | 13,511,127 |
Companies Similar to ELAN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Envista Holdings Corp
COOPER COMPANIES, INC.
Teladoc Health, Inc.
Fortrea Holdings Inc.
PFIZER INC
Enovis CORP
Viatris Inc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ELAN on your watchlist
Track score changes the day Elanco Animal Health Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ELAN a good stock to buy?
13F Pro's AI-powered analysis of Elanco Animal Health Inc (ELAN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELAN are available on the ELAN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ELAN is classified as a large company.
Which hedge funds own ELAN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELAN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Elanco Animal Health Inc's investment landscape.